OR Oncology Reports 1021-335X 1791-2431 D.A. Spandidos 10.3892/or.2014.3061 or-31-05-2206 Articles Aberrant CpG island methylation of PTEN is an early event in nasopharyngeal carcinoma and a potential diagnostic biomarker LIJINBANG12 GONGPINGGUI1 LYUXIAOMING2 YAOKAITAI2 LIXIN2 PENGHONG1 Department of Otolaryngology-Head and Neck Surgery, Nanfang Hospital, Guangzhou, Guangdong 510515, P.R. China Cancer Research Institute and the Provincial Key Laboratory of Functional Proteomics, Southern Medical University, Guangzhou, Guangdong 510515, P.R. China Correspondence to: Professor Hong Peng, Department of Oto-laryngology-Head and Neck Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong 510515, P.R. China, E-mail: hongpeng2005@hotmail.com. Professor Xin Li, Cancer Research Institute and the Provincial Key Laboratory of Functional Proteomics, Southern Medical University, Guangzhou, Guangdong 510515, P.R. China, E-mail: xinli268@gmail.com 5 2014 05 03 2014 31 5 2206 2212 27 11 2013 14 01 2014 Copyright © 2014, Spandidos Publications 2014 This is an open-access article licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. The article may be redistributed, reproduced, and reused for non-commercial purposes, provided the original source is properly cited.

The inactivation of phosphatase and tensin homolog (PTEN) due to its CpG island hypermethylation has been observed in some types of tumors except nasopharyngeal carcinoma (NPC). In the present study, we focused on the aberrant methylation of PTEN CpG islands in NPC. The mRNA expression of PTEN was detected by quantitative PCR in 45 NPC and 22 non-tumor nasopharyngeal epithelial (NP) tissues. The methylation status of PTEN was examined by methylation-specific polymerase chain reaction and sequencing. The mRNA expression of PTEN in three NPC cell lines treated with 5-aza-2′-deoxycytidine (5-aza-dC) was also examined. PTEN was downregulated in both NPC tissues and NPC cell lines and a relatively higher methylation level of PTEN was found in NPC specimens (82.2%) relative to NP tissues (5.3%). The PTEN mRNA expression was restored in NPC cell lines by treatment with 5-aza-dC. These results first reveal an epigenetic alteration, aberrant methylation of PTEN, in NPC, which is probably an early event and may be regarded as a novel candidate biomarker for early stage of NPC detection and prevention.

 methylation phosphatase and tensin homolog nasopharyngeal carcinoma biomarker Introduction

Nasopharyngeal carcinoma (NPC) is a malignancy particularly prevalent in the southern Chinese population of Guangdong, in the Inuit population of Alaska and in native Greenlanders (1,2). The 5-year survival rates of stage I and II NPC range from 72 to 90%; however, the 5-year survival rates of stage III and IV drop to 55 and 30% (3). NPC detection rate and early diagnosis are major factors adversely affecting the effect of treatment (4). Finding a biomarker detecting early stage of NPC remains the most promising to facilitate the early NPC diagnosis and therapy, probably improving the long-term survival of patients.

Phosphatase and tensin homolog (PTEN) has been identified and mapped to chromosome 10q23 (5). Considerable attention has been paid to the tumor suppressor gene PTEN, since it may suppress tumor cell growth by antagonizing protein tyrosine kinases and regulate the first step of tumor cell invasion and metastasis through its interaction with focal adhesions (5,6). The loss of function of PTEN leads to increases in cellular proliferation, survival and growth in many types of cancer (7). Recombinant PTEN is able to dephosphorylate phosphatidylinositol 3,4,5-trisphosphate and phosphatidylinositol 3,4-bisphosphate as well as antagonize the phosphoinositide 3-kinase pathway (8). Notably, CpG island hypermethylation has been identified as an alternative mechanism of PTEN inactivation in cancers including lung cancer, endometrial carcinoma, prostate cancer, brain tumors, EBV-associated gastric carcinoma, cervical neoplasm, malignant melanoma and hematologic malignancies (9–17). However, to date, this mechanism of PTEN inactivation has not been reported in NPC.

In the present study, we evaluated the PTEN expression in NPC specimens and control samples by quantitative RT-PCR (qPCR) and examined the CpG island methylation status of PTEN using methylation-specific polymerase chain reaction (MSP) and sequencing. 5-aza-dC treatment can lead to DNA demethylation via inhibition of DNA methyltransferase activity (18). We also treated NPC cell lines (HONE1, CNE1 and 6–10B) with 5-aza-dC and then examined PTEN expression. Thus, we preliminarily demonstrated the role of PTEN methylation in relation to the mechanism of PTEN inactivation in NPC.

 Materials and methods Methylation-specific PCR

The methylation status of the PTEN promoter region was determined by MSP using bisulfite-modified DNA. The targets of the promoter regions were one site. The sequences of the methylated and unmethylated primer pairs are listed in Table I with the other primer sequences used in the study. DNA was modified by the bisulfite reaction using an EpiTect Bisulfite kit (Qiagen). Methylated and unmethylated genomic regions can be distinguished by PCR using each sequence-specific pair of primers. MSP experiments were performed at least in duplicate.

 Patients and tissue samples

All NPC and NP samples were collected from the Department of Otorhinolaryngology, Head and Neck Surgery, Nanfang Hospital, Affiliated Hospital of Southern Medical University, Guangzhou, China. For the use of these clinical materials for research purposes, prior written informed consent and ethics approval were obtained from all participants and the Ethics Committees of the Nanfang Hospital, respectively.

 Cells and culture conditions

NPC cell lines (5–8F, CNE1, CNE2, 6–10B, SUNE1 and HONE1) were available from the Cancer Institute of Southern Medical University (Guangzhou, China). All cell lines used in the present study were maintained in DMEM medium (Invitrogen) with 10% FBS (HyClone), 100 U/ml penicillin, 100 mg/ml streptomycin (Invitrogen), and incubated at 5% CO2 at 37°C.

 Quantitative RT-PCR (qRT-PCR)

Total RNA of tissues and cells was reverse transcribed using PrimeScript® RT reagent kit (Takara). Quantitative real-time PCR was performed using SYBR® Premix Ex Taq™ II (Takara) on a StrataGene Mx3005P System. The sequences of the qPCR primer pairs are listed in Table I.

 Cell viability assay

Cell viability was analyzed using an MTT assay (Sigma, St. Louis, MO, USA). Briefly, 1×103 cells were seeded into a 96-well plate with quadruplicate repeat for each condition. After 24 h of incubation, MTT reagent was added to each well and incubated for 4 h. The formazan crystals formed by viable cells were then solubilized in DMSO and measured at 490 nm for the absorbance values. Each experiment was performed in triplicate. The 5-aza-dC concentration required to inhibit cell growth by 50% (IC50) was calculated from survival curves. Survival percent was calculated using the following formula: Survival percent (%) = (mean experimental absorbance/mean control absorbance) × 100%.

 Statistical analysis

The data are presented as mean ± SEM, unless otherwise indicated, of at least three independent experiments. Statistical analysis was performed using an SPSS 13.0 package system. Statistical significance was assessed by the Student’s t-test, the Pearson’s Chi-square test, Fisher’s exact test or one-way ANOVA analysis (*P<0.05; **P<0.01; ***P<0.001).

 Results PTEN is downregulated in clinical NPC specimens and human NPC cell lines

We first examined the expression level of PTEN in 45 NPC specimens and 22 non-tumor nasopharyngeal epithelial (NP) tissues. The average expression level of PTEN was significantly lower in NPC specimens compared with non-tumor NP tissues (Fig. 1B; P<0.0001). A panel of human NPC cell lines was also analyzed for the expression level of PTEN. Similarly, the expression level of PTEN was observed to be decreased in all 5 NPC cell lines compared with the non-tumor NP tissues (Fig. 1A). These data supported that PTEN was downregulated in NPC.

 Hypermethylation of PTEN in clinical NPC specimens and human NPC cell lines

In order to explore the potential role of CpG island methylation in the transcriptional silencing of the PTEN gene, we investigated the methylation status of PTEN in clinical specimens and NPC cell lines. As the 5′ region of PTEN contained many CpG islands spanning ~3 kb, we focused only on its promoter region (Fig. 2A) in the present study.

Our MSP analysis showed that CpG islands in the PTEN promoter region were methylated in 82.2% (37/45) of NPC tissues, whereas the methylated PTEN appeared in only 5.3% (1/19) of the non-tumor NP tissues (Fig. 2B) and in 80% (4/5) of NPC cell lines (Fig. 2C). The difference in the hypermethylation level between NPC tissues and non-tumor NP tissues was statistically significant (P<0.0001).

To validate MSP results, we sequenced M-MSP and U-MSP products amplified from two NPC tissues using either M or U primers of PTEN. The sequencing results showed that all the cytosine residues in the M-MSP product were converted to thymines, except for those in CpG dinucleotides, indicating the presence of methylated cytosines in these CpG dinucleotides. The representative sequencing results of M- and U-MSP products of PTEN are shown in Fig. 2D.

 Restoration of PTEN in NPC cell lines after 5-aza-dC treatment

To directly test the effect of promoter methylation on PTEN inactivation, we treated 3 NPC cell lines (HONE-1, CNE1 and 6–10B) with 5-aza-dC for 3 days (Fig. 3A), and then examined PTEN mRNA expression changes. We observed that PTEN mRNA expression was clearly upregulated in all 3 NPC cell lines after 5-aza-dC treatment (Fig. 3B). These results suggested that methylation of promoter region plays a regulatory role in silencing the expression of PTEN in NPC cells.

 PTEN mutation in NPC cell lines

To detect the mutation of tumor suppressor PTEN in NPC, DNA sequencing was used to detect the mutation from exon 1 to exon 6 (Fig. 4A) of the PTEN gene in 6 NPC cell lines (5–8F, CNE1, CNE2, 6–10B, SUNE1 and HONE1). None of the NPC cell lines showed mutation in exon 1 to exon 6 of the PTEN gene (Fig. 4B).

 Discussion

NPC is one of the most common types of cancer in southern China. In contrast to other head and neck malignancies, NPC is highly sensitive to radiation and chemotherapy. High survival rates are reported for early stage (stages I and II) of diseases, but the prognosis for advanced stage (stages III and IV) remains poor; in patients with advanced NPC at the local site or with distant metastases, the disease will subsequently recur in 30–40% (19). Unfortunately, the majority of NPCs are diagnosed at an advanced stage due to the difficulty of a thorough nasopharyngeal exam, as well as non-specific presenting symptoms (cervical nodal enlargement, headache, nasal and aural dysfunction). In light of these, the molecular targets for early diagnosis of NPC need to be clarified.

In NPC, gene silencing by deletion, insertion and mutation of tumor suppressor genes (TSGs), such as p53 (20), are uncommon events in carcinogenesis. The present study demonstrated that no mutation was found in functional DNA regions of PTEN by PCR sequencing, which is in accordance with the results by PCR-SSCP in NPC. Downregulation of TSG expression by aberrant methylation is increasingly emerging as an important mechanism of nasopharyngeal tumorigenesis (21–24).

Phosphatase and tensin homolog (PTEN) deleted on chromosome 10 was originally cloned as a tumor suppressor. It has been confirmed that PTEN is deleted or inactivated in many tumor types, including renal (25), melanoma (26), endometrial (27), breast (5), prostate (5), lung (9), bladder (28), thyroid (29) and NPC (30), identifying PTEN as an important tumor suppressor. On the other hand, promoter methylation is widely considered to be an important epigenetic mechanism in the carcinogenesis of NPC, and has been proven promising for early diagnosis of multiple types of tumors (31–33).

To the best of our knowledge, this is the first study to demonstrate an essential role of PTEN methylation in the carcinogenesis of NPC. We found that 82.2% (37/45) of NPC specimens and 80% (4/5) of NPC cell lines present PTEN CpG island DNA methylation, compared with 5.3% (1/19) of non-tumor NP tissues; PTEN methylation was not related to age, gender, lymphatic node metastasis and tumor local grade (Table II). However, our present study did not demonstrate a significant difference between methylation frequency in early and late stage NPC cases. Considering PTEN expression in tumor specimens and cell lines (Table III), PTEN methylation may be an early event in the carcinogenesis of NPC. As to whether the epigenetic change of PTEN is one of the potential markers for early diagnosis, a profound study is currently in progress in the local high risk population and preclinical disease.

In brief, our more recent studies indicated that PTEN methylation and loss of PTEN expression are early events in the development of NPC and may serve as a biomarker for early diagnosis.

 Acknowledgements

This study was sponsored by NSFC of China (no. 81172585) and Guangdong SFC (nos. S2011010003828 and S2013010016388).

 References ParkinDMMuirCSCancer incidence in five continentsComparability and quality of dataIARC Sci Publ451731992 NielsenNHMikkelsenFHansenJPNasopharyngeal cancer in Greenland. The incidence in an Arctic Eskimo populationActa Pathol Microbiol Scand A858508581977 DeNittisASLiuLRosenthalDIMachtayMNasopharyngeal carcinoma treated with external radiotherapy, brachytherapy, and concurrent/adjuvant chemotherapyAm J Clin Oncol2593952002 SanguinetiGGearaFBGardenASCarcinoma of the nasopharynx treated by radiotherapy alone: determinants of local and regional controlInt J Radiat Oncol Biol Phys379859961997 LiJYenCLiawDPTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancerScience275194319471997 LiottaLATumor invasion and metastases - role of the extracellular matrix: Rhoads Memorial Award lectureCancer Res46171986 LeslieNRDownesCPPTEN function: how normal cells control it and tumour cells lose itBiochem J3821112004 WuXSenechalKNeshatMSWhangYESawyersCLThe PTEN/MMAC1 tumor suppressor phosphatase functions as a negative regulator of the phosphoinositide 3-kinase/Akt pathwayProc Natl Acad Sci USA9515587155911998 SoriaJCLeeHYLeeJILack of PTEN expression in non-small cell lung cancer could be related to promoter methylationClin Cancer Res8117811842002 SalvesenHBMacDonaldNRyanAPTEN methylation is associated with advanced stage and microsatellite instability in endometrial carcinomaInt J Cancer9122262001 CairnsPOkamiKHalachmiSFrequent inactivation of PTEN/MMAC1 in primary prostate cancerCancer Res57499750001997 WienckeJKZhengSJellumaNMethylation of the PTEN promoter defines low-grade gliomas and secondary glioblastomaNeuro Oncol92712792007 HinoRUozakiHMurakamiNActivation of DNA methyltransferase 1 by EBV latent membrane protein 2A leads to promoter hypermethylation of PTEN gene in gastric carcinomaCancer Res69276627742009 KangYHLeeHSKimWHPromoter methylation and silencing of PTEN in gastric carcinomaLab Invest822852912002 FurutaJUmebayashiYMiyamotoKPromoter methylation profiling of 30 genes in human malignant melanomaCancer Sci959629682004 Montiel-DuarteCCordeuLAgirreXResistance to Imatinib Mesylate-induced apoptosis in acute lymphoblastic leukemia is associated with PTEN down-regulation due to promoter hypermethylationLeuk Res327097162008 CheungTHLoKWYimSFEpigenetic and genetic alternation of PTEN in cervical neoplasmGynecol Oncol936216272004 JonesPATaylorSMCellular differentiation, cytidine analogs and DNA methylationCell2085931980 TeoPYuPLeeWYSignificant prognosticators after primary radiotherapy in 903 nondisseminated nasopharyngeal carcinoma evaluated by computer tomographyInt J Radiat Oncol Biol Phys362913041996 SunYHegamyerGChengYJAn infrequent point mutation of the p53 gene in human nasopharyngeal carcinomaProc Natl Acad Sci USA89651665201992 ZhangZSunDVan DoNTangAHuLHuangGInactivation of RASSF2A by promoter methylation correlates with lymph node metastasis in nasopharyngeal carcinomaInt J Cancer12032382007 MoYMidorikawaKZhangZPromoter hypermethylation of Ras-related GTPase gene RRAD inactivates a tumor suppressor function in nasopharyngeal carcinomaCancer Lett3231471542012 ShuXSLiLJiMFEZF2, a novel 3p14 tumor suppressor gene, represses oncogene EZH2 and MDM2 expression and is frequently methylated in nasopharyngeal carcinomaCarcinogenesis34198419932013 LiLTaoQJinHThe tumor suppressor UCHL1 forms a complex with p53/MDM2/ARF to promote p53 signaling and is frequently silenced in nasopharyngeal carcinomaClin Cancer Res16294929582010 BrennerWFarberGHergetTLehrHAHengstlerJGThuroffJWLoss of tumor suppressor protein PTEN during renal carcinogenesisInt J Cancer9953572002 GuldbergPThorSPBirckAAhrenkielVKirkinAFZeuthenJDisruption of the MMAC1/PTEN gene by deletion or mutation is a frequent event in malignant melanomaCancer Res57366036631997 OdaKStokoeDTaketaniYMcCormickFHigh frequency of coexistent mutations of PIK3CA and PTEN genes in endometrial carcinomaCancer Res6510669106732005 CairnsPEvronEOkamiKPoint mutation and homozygous deletion of PTEN/MMAC1 in primary bladder cancersOncogene16321532181998 LiawDMarshDJLiJGermline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndromeNat Genet1664671997 QuCLiangZHuangJMiR-205 determines the radioresistance of human nasopharyngeal carcinoma by directly targeting PTENCell Cycle117857962012 MutterGLLinMCFitzgeraldJTAltered PTEN expression as a diagnostic marker for the earliest endometrial precancersJ Natl Cancer Inst929249302000 HeynHCarmonaFJGomezADNA methylation profiling in breast cancer discordant identical twins identifies DOK7 as novel epigenetic biomarkerCarcinogenesis341021082013 SunDZhangZVan DoNHuangGErnbergIHuLAberrant methylation of CDH13 gene in nasopharyngeal carcinoma could serve as a potential diagnostic biomarkerOral Oncol4382872007

The expression of PTEN is reduced in NPC cell lines and clinical specimens. (A) Expression of PTEN in 5 NPC cell lines. (B) Average expression level of PTEN in human NPC specimens (n=45) and non-tumor nasopharyngeal epithelial (NP) tissues (n=22). mRNA abundance was normalized to GAPDH mRNA. Each bar represents the means ± SD of three experiments.

Hypermethylation of the PTEN gene in human NPC cell lines and clinical specimens. (A) Schematic representation of the human PTEN promoter. The CpG island of PTEN extends from -2011 to +1390 from TSS. Each pink tick mark represents one CpG site. The arrows indicate the TSS. Methylation-specific PCR (MSP) assay to determine methylation status was carried out on 8 CpG sites in its primer region, as underlined by the arrows. TSS, transcriptional start site. (B) Detection of hypermethylation of PTEN in nasopharyngeal epithelial (NP) and NPC tissues, respectively. (C) Detection of hypermethylation of PTEN in NPC cell lines. MSP analysis was performed using primers specifically for methylated (M) or unmethylated (U) CpG sites of PTEN gene. PCR products were visualized after electrophoresis on a 2% agarose gel. (D) Sequencing analysis of M and U products of MSP for PTEN in NPC tissues. For M products, all cytosines were changed to thymines, except those in CpG dinucleotides. For M products, all cytosines were changed to thymines, with those in CpG dinucleotides. Arrows show the cytosines in CpG dinucleotides.

Re-expression of PTEN in NPC cell lines after 5-aza-dC treatment. (A) Effect of various concentrations of 5-aza-dC on the growth of NPC cell lines. The 5-aza-dC concentration required to inhibit cell growth by 50% (IC50) was calculated from survival curves. (B) MSP/USP results of NPC cell lines treated with either vehicle or 5-aza-dC for 72 h; 5-aza-dC treatment leads to DNA demethylation. Data are presented as the average of triplicate measurements from duplicate experiments. qRT-PCR in NPC cell lines showed detection of PTEN mRNA following treatment with 5-aza-dC. Each bar represents the means ± SD of three experiments. *P<0.05; **P<0.01.

DNA sequencing from exon 1 to exon 6 of the PTEN gene in 6 NPC cell lines. (A) Schematic representation of the human PTEN exons. The arrows indicate the TIS. TIS, transcriptional initiation site. PCR primers to detect mutation status are underlined by the arrows. (B) Sequence analysis of the PCR product from exon 1 TIS region of the PTEN gene in 6 NPC cell lines.

Summary of the primers used in the present study.

Primer Sequence Sequence product size (bp) Annealing temperature (°C)
qRT-PCR
 GAPDH-forward 5′-CATGGGTGTGAACCATGAGA-3′ 165 60
 GAPDH-reverse 5′-GTCTTCTGGGTGGCAGTGAT-3′
 PTEN-forward 5′-TGCAGAAGAAGCCCCGCCA-3′ 208 60
 PTEN-reverse 5′-ACGCCTTCAAGTCTTTCTGCAGG-3′
Methylated specific PCR assay
 Methylated
  PTEN-forward 5′-TTCGTTCGTCGTCGTCGTATTT-3′ 207 58
  PTEN-reverse 5′-GCCGCTTAACTCTAAACCGCAA-3′
 Unmethylated
  PTEN-forward 5′-GTGTTGGTGGAGGTAGTTGTTT-3′ 163 58
  PTEN-reverse 5′-ACCACTTAACTCTAAACCACAACCA-3′
PCR primers for 6 PTEN exons
 Exon 1-forward 5′-TTCTGCCATCTCTCTCCTCC-3′ 194 60
 Exon 1-reverse 5′-ATCCGTCTACTCCCACGTTC-3′
 Exon 2-forward 5′-GTTTGATTGCTGCATATTTCA-3′ 201 50
 Exon 2-reverse 5′-TCTAAATGAAAACACAACATGAA-3′
 Exon 3-forward 5′-AGCTCATTTTTGTTAATGGTGG-3′ 178 60
 Exon 3-reverse 5′-CCTCACTCTAACAAGCAGATAACTTTC-3′
 Exon 4-forward 5′-AAAGATTCAGGCAATGTTTGTTAG-3′ 200 60
 Exon 4-reverse 5′-TGACAGTAAGATACAGTCTATCGGG-3′
 Exon 5-1-forward 5′-TTTTTTCTTATTCTGAGGTTATC-3′ 184 50
 Exon 5-1-reverse 5′-TCATTACACCAGTTCGTCC-3′
 Exon 5-2-forward 5′-TCATGTTGCAGCAATTCAC-3′ 176 50
 Exon 5-2-reverse 5′-GAAGAGGAAAGGAAAAACATC-3′
 Exon 6-forward 5′-ATGGCTACGACCCAGTTACC-3′ 284 60
 Exon 6-reverse 5′-AAGAAAACTGTTCCAATACATGG-3′

Association between PTEN methylation and clinicopathological parameters of NPC.

PTEN methylation
Total no. Positive n/total (%) Negative n/total (%) P-valuea
Gender
 Male 36 30/36 (83.3) 6/36 (16.7) 0.65
 Female 9 7/9 (77.8) 2/9 (22.2)
Age (years)
 <60 35 28/35 (80) 7/35 (20) 0.66
 ≥60 10 9/10 (90) 1/10 (10)
T gradeb
 1, 2 31 27/31 (87.1) 4/31 (12.9) 0.23
 3, 4 14 10/14 (71.4) 4/14 (28.6)
N stageb
 0 7 6/7 (85.7) 1/7 (14.3) 1
 1, 2, 3, 4 38 31/38 (81.6) 7/38 (18.4)
Stageb
 I, II 20 18/20 (90) 2/20 (10) 0.27
 III, IV 25 19/25 (76) 6/25 (24)
Histology
 Keratinizing squamous cell carcinoma 45 37/45 (82.2) 8/45 (17.8)
 Non-keratinizing carcinoma 0

Comparisons were made by Pearson’s Chi-square test or Fisher’s exact test (SPSS 13).

Staging according to the International Union Against Cancer (UICC).

Summary of the PTEN methylation in human tumor/normal tissues and cell lines.

Tumor type (Ref.) Testing method Histology Methylation rate Tumor cell lines Methylation rate
Lung cancer (9) MSP PTEN-negative NSCLC 7/20 (35) NSCLC cell lines 11/16 (69)
MSP PTEN-positive NSCLC 0/10 (0)
Endometrial carcinoma (10) MSP Endometrial carcinoma 26/138 (19)
Prostate cancer (11) MSP Primary prostate tumor 0/6 (0)
Brain tumor (12) MSP Non-tumor brain 0/13 (0)
Gliomas 44/90 (49)
EBV-associated gastric carcinoma (13) MSP EBV-negative gastric cancer 26/87 (30)
EBV-associated gastric cancer 18/28 (64)
Malignant melanomaa (15) MSP Malignant melanoma Melanoma cell lines 3/13 (23)
Gastric cancer (14) MSP Gastric cancer 26/66 (39)
PTEN-negative gastric cancer 19/26 (73)
Cervical neoplasm (17) MSP CIN-Hb 4/10 (40)
Squamous cell carcinoma 36/62 (58)
Nasopharyngeal carcinoma (present study) MSP Nasopharyngeal epithelial 1/19 (5.3) NPC cell lines 4/5 (80)
Nasopharyngeal carcinoma 37/45 (82.2)

PTEN did not show complete methylation in malignant melanoma tissues.

CIN-H, high-grade cervical intraepithelial neoplasia. The methylation rate is expressed as n/total (%).